Venus Continues To Drive TAVR In China By Licensing In Australian Start-Up Tech
Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.
You may also be interested in...
Minute Insight: Venus Buys Transcatheter Valve Developer Cardiovalve For $300M
Israel-based Cardiovalve is developing a transcatheter valve replacement system to treat mitral and tricuspid valve regurgitation.
China's Venus Persists With Global TAVR Solutions Expansion
Venus Medtech, the Chinese transcatheter aortic valve technology specialist, has made its second international acquisition as it pursues its strategy for global expansion in the TAVR market.
Investor Eye: A Licensing-Based Approach May Be Best For Revolutionary IP
Keeping a firm grip on one’s IP is a cornerstone of most innovative businesses. However, Robert Cote, CEO of Cote Capital, believes that if the idea is good enough to keep close, it’s good enough to license out.